Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.11 (market cap $44.49B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 19.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| JEPQ | SLS | |
|---|---|---|
Market Cap | $44.49B | $2.27B |
Volume | 5,681,789 | 4,179,659 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $15.46 |
52-Week Low | $53.77 | $1.39 |
Typical Hold Time | 66 Days | — |
Enterprise Value | — | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.09, down 0.29% on the day, with a bullish technical signal driven by moving averages. The ETF maintains strong income generation through its covered-call strategy, with recent monthly dividends ranging from $0.57 to $0.70. Technical analysis shows support at $60-61 and resistance at $61-62, while oscillators remain neutral with RSI at 47.13.
JEPQ offers high monthly income potential with an estimated 11% yield, though its covered-call strategy limits upside appreciation. The ETF provides exposure to Nasdaq technology stocks with downside protection during volatility. Key risks include market correlation, income variability, and competition from other income ETFs. Institutional interest remains strong, with Envestnet recently increasing its position.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
